Related Experiment Video
Updated: Apr 23, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Posttranslational modifications of RUNX1 as potential anticancer targets
S Goyama1, G Huang1, M Kurokawa2
1Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
RUNX1 is crucial in blood cell formation and cancer. Targeting its post-translational modifications (PTMs) offers a promising strategy for developing novel anticancer therapies.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- RUNX1 is a key transcription factor regulating hematopoiesis.
- RUNX1's dysregulation is linked to hematopoietic neoplasms and solid tumors, acting as both a promoter and suppressor.
- RUNX1's role in cancer makes it a significant therapeutic target.
Purpose of the Study:
- To review the context- and dosage-dependent roles of RUNX1 in various neoplasms.
- To provide a comprehensive overview of RUNX1 post-translational modifications (PTMs).
- To discuss the contribution of aberrant RUNX1 PTMs to tumorigenesis and explore therapeutic strategies targeting these modifications.
Main Methods:
- Literature review of existing studies on RUNX1 in cancer.
- Analysis of biochemical and biological data on RUNX1 PTMs.
- Discussion of therapeutic implications of targeting RUNX1 PTMs.
Main Results:
- RUNX1 PTMs, including phosphorylation, acetylation, methylation, and ubiquitination, critically regulate its activity.
- These PTMs influence RUNX1-mediated transcription, protein degradation, and interactions, impacting cancer development.
- Aberrant PTMs of RUNX1 are implicated in tumorigenesis.
Conclusions:
- Targeting RUNX1 PTMs presents a viable strategy for developing novel anticancer therapies.
- Understanding RUNX1's multifaceted roles and PTMs is essential for effective cancer treatment.
- Further research into RUNX1 PTMs can unlock new therapeutic avenues for various cancers.
More Related Videos
08:12Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins
Published on: January 8, 2018
11:42Genome-wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN
Published on: April 3, 2026
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Epigenetic Regulation
X-chromosome...